broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K74514084-003-09-2 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 0.811861 | -1.178738 | -0.129052 | 0.91029 | 0.062279 | null | pazopanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3 | oncology | renal cell carcinoma (RCC), soft tissue sarcoma (STS) | CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1 | Launched | true | ACH-001190 |
BRD-K75009076-001-02-1 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 0.075392 | 1.932777 | 0.660152 | 0.722707 | 0.54553 | 0.593671 | SCH-900776 | CHK inhibitor | CDK2, CHEK1 | null | null | Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1 | Phase 2 | true | ACH-001190 |
BRD-K76239644-001-02-6 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 0.928059 | -3.325055 | -0.201904 | 0.962543 | 0.095447 | null | BMS-690514 | EGFR inhibitor, VEGFR inhibitor | EGFR, ERBB2, FLT3, KDR | null | null | COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1 | Phase 2 | true | ACH-001190 |
BRD-K76674262-001-03-3 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 0.118296 | 2.264091 | 0.588164 | 0.707185 | 0.398505 | 0.44897 | homoharringtonine | protein synthesis inhibitor | RPL3 | hematologic malignancy | chronic myeloid leukemia (CML) | COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC | Launched | true | ACH-001190 |
BRD-K76908866-001-07-6 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 1.39432 | 6.802555 | 0.378062 | 1 | 1.269847 | null | CP-724714 | EGFR inhibitor, protein tyrosine kinase inhibitor | ERBB2 | null | null | COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1 | Phase 2 | true | ACH-001190 |
BRD-K77625799-001-07-7 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 2.626525 | 0.422014 | 0.1055 | 1 | 32.700013 | null | vandetanib | EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA | oncology | medullary thyroid cancer (MTC) | COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1 | Launched | true | ACH-001190 |
BRD-K78431006-001-15-1 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 0.550315 | -0.057178 | -0.02581 | 0.823619 | 0.000035 | null | crizotinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl | Launched | true | ACH-001190 |
BRD-K79254416-001-21-8 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | -0.041841 | 0.254083 | 0.157641 | 0.555138 | 0.286443 | 0.208775 | decitabine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML) | Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1 | Launched | true | ACH-001190 |
BRD-K81016934-001-02-0 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 1.116322 | -0.089833 | -0.079971 | 1 | 3,465.245749 | null | INC-280 | c-Met inhibitor | MET | null | null | CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1 | Phase 2 | true | ACH-001190 |
BRD-K81418486-001-44-2 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | -0.01387 | 0.858552 | 0.716181 | 0.713857 | 0.724166 | 0.701456 | vorinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9 | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1 | Launched | true | ACH-001190 |
BRD-K81473043-001-19-5 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 0.559678 | 3.1692 | 0.507811 | 0.892666 | 0.058683 | null | tanespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 3 | true | ACH-001190 |
BRD-K82135108-001-04-3 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 1.472776 | -0.237027 | 0.105086 | 1 | 0.041446 | null | elesclomol | oxidative stress inducer | HSPA1A | null | null | CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1 | Phase 3 | true | ACH-001190 |
BRD-K82746043-001-19-3 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 1.18667 | 2.333626 | 0.234316 | 1 | 0.027103 | null | navitoclax | BCL inhibitor | BCL2, BCL2L1, BCL2L2 | null | null | CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 | Phase 2 | true | ACH-001190 |
BRD-K82818427-001-04-8 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 0.61966 | 0.195052 | 0.123003 | 0.855313 | 1.140325 | null | batimastat | matrix metalloprotease inhibitor | ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8 | null | null | CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO | Phase 3 | true | ACH-001190 |
BRD-K83029223-001-01-3 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 0.12147 | 3.243717 | 0.818348 | 0.529717 | 0.003464 | 0.003774 | litronesib | kinesin-like spindle protein inhibitor | KIF11 | null | null | CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 | Phase 2 | true | ACH-001190 |
BRD-K83988098-001-02-0 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 0.355537 | 5.30532 | 0.492401 | 0.907174 | 0.03856 | 0.048728 | alvespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 2 | true | ACH-001190 |
BRD-K85402309-043-01-9 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 0.709558 | -0.158864 | -0.027259 | 0.811283 | 4.595101 | null | dovitinib | EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB | null | null | CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O, CN1CCN(CC1)c1ccc2nc([nH]c2c1)-c1c(N)c2c(F)cccc2[nH]c1=O | Phase 3 | true | ACH-001190 |
BRD-K85606544-001-09-1 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | -0.232821 | 0.444083 | 0.000193 | 0.995095 | 90,049.774084 | null | neratinib | EGFR inhibitor | EGFR, ERBB2, KDR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(OCc4ccccn4)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 3 | true | ACH-001190 |
BRD-K86118762-001-01-8 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 1.210815 | 1.560414 | -0.061769 | 1 | 0.001922 | null | linsitinib | IGF-1 inhibitor | IGF1R, INSR, INSRR | null | null | C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12, C[C@@]1(O)C[C@@H](C1)c1nc(-c2ccc3ccc(nc3c2)-c2ccccc2)c2c(N)nccn12 | Phase 3 | true | ACH-001190 |
BRD-K86972824-001-01-4 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 1.648706 | 1.663756 | 0.4455 | 1 | 3.948083 | null | oltipraz | nuclear factor erythroid derived, like (NRF2) activator | ANG | null | null | Cc1c(ssc1=S)-c1cnccn1, Cc1c(ssc1=S)-c1cnccn1 | Phase 3 | true | ACH-001190 |
BRD-K87737963-001-06-0 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 0.958758 | -0.105367 | -0.025582 | 0.969716 | 1,466.977927 | null | cyt387 | null | JAK1, JAK2, JAK3 | null | null | O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1, O=C(NCC#N)c1ccc(cc1)-c1ccnc(Nc2ccc(cc2)N2CCOCC2)n1 | Phase 3 | true | ACH-001190 |
BRD-K87782578-001-01-4 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 0.909457 | -0.560217 | -0.000766 | 0.932841 | 1.306381 | null | AVL-292 | Bruton's tyrosine kinase (BTK) inhibitor | BTK, YES1 | null | null | COCCOc1ccc(Nc2ncc(F)c(Nc3cccc(NC(=O)C=C)c3)n2)cc1 | Phase 2 | true | ACH-001190 |
BRD-K87909389-003-03-4 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 0.117781 | 3.261754 | 0.819504 | 0.685909 | 0.315848 | 0.342962 | alvocidib | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, EGFR, PYGM | null | null | CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl, CN1CC[C@@H]([C@H](O)C1)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-001190 |
BRD-K88510285-001-17-8 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 0.071203 | 0.756267 | 0.700538 | 0.427031 | 0.005881 | 0.007205 | bortezomib | NFkB pathway inhibitor, proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMD1, PSMD2, RELA | hematologic malignancy | multiple myeloma, mantle cell lymphoma (MCL) | CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O, CC(C)C[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O | Launched | true | ACH-001190 |
BRD-K89014967-001-04-3 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 0.15239 | 0.322326 | 0.42398 | 0.568614 | 0.068393 | 0.211261 | AS-703026 | MEK inhibitor | MAP2K1, MAP2K2 | null | null | OC[C@@H](O)CNC(=O)c1ccncc1Nc1ccc(I)cc1F | Phase 2 | true | ACH-001190 |
BRD-K92441787-001-04-1 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 0.839592 | -6.737949 | 0.054069 | 0.896899 | 0.312085 | null | bexarotene | retinoid receptor agonist | RXRA, RXRB, RXRG | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | Cc1cc2c(cc1C(=C)c1ccc(cc1)C(O)=O)C(C)(C)CCC2(C)C | Launched | true | ACH-001190 |
BRD-K92723993-001-17-4 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 3.458803 | 1.265267 | 0.133339 | 1 | 45.777382 | null | imatinib | Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET | hematologic malignancy, oncology | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST) | CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1, CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1 | Launched | true | ACH-001190 |
BRD-K95142244-001-01-5 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 1.536969 | 2.91696 | 0.163115 | 1 | 0.023376 | null | talazoparib | PARP inhibitor | PARP2 | null | null | Cn1ncnc1[C@@H]1[C@H](Nc2cc(F)cc3c2c1n[nH]c3=O)c1ccc(F)cc1 | Phase 3 | true | ACH-001190 |
BRD-K96123349-236-02-8 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 2.601371 | 5.034488 | 0.12825 | 1 | 7.852997 | null | brequinar | dihydroorotate dehydrogenase inhibitor | DHODH | null | null | Cc1c(nc2ccc(F)cc2c1C(O)=O)-c1ccc(cc1)-c1ccccc1F | Phase 2 | true | ACH-001190 |
BRD-K98572433-001-02-9 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 2.592751 | 0.204212 | 0.406249 | 1 | 1.415087 | null | AZD8931 | EGFR inhibitor | EGFR, ERBB2, ERBB3 | null | null | CNC(=O)CN1CCC(CC1)Oc1cc2c(Nc3cccc(Cl)c3F)ncnc2cc1OC | Phase 2 | true | ACH-001190 |
BRD-K99113996-001-02-0 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 0.928581 | 0.387881 | 0.026842 | 0.973636 | 0.452589 | null | AZD2014 | mTOR inhibitor | MTOR | null | null | CNC(=O)c1cccc(c1)-c1ccc2c(nc(nc2n1)N1CCOC[C@@H]1C)N1CCOC[C@@H]1C | Phase 2 | true | ACH-001190 |
BRD-K99616396-001-05-1 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 1.223511 | 1.236139 | 0.144411 | 1 | 1.398458 | null | motesanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT1, FLT4, KDR, KIT | null | null | CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12, CC1(C)CNc2cc(NC(=O)c3cccnc3NCc3ccncc3)ccc12 | Phase 3 | true | ACH-001190 |
BRD-K99749624-001-07-0 | ACH-001190 | SKMEL2_SKIN | MTS010 | 1 | 1.296013 | -0.07955 | 0.010793 | 1 | 0.943975 | null | linifanib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK | null | null | Cc1ccc(F)c(NC(=O)Nc2ccc(cc2)-c2cccc3[nH]nc(N)c23)c1 | Phase 3 | true | ACH-001190 |
BRD-A74914197-001-02-9 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.448239 | 0.926788 | 0.210181 | 0.798351 | 0.018696 | 0.216038 | pralatrexate | dihydrofolate reductase inhibitor | DHFR, TYMS | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | Nc1nc(N)c2nc(CC(CC#C)c3ccc(cc3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)cnc2n1 | Launched | true | ACH-001239 |
BRD-K02113016-001-19-6 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.724528 | -0.66657 | 0.146572 | 0.906019 | 0.014339 | null | olaparib | PARP inhibitor | PARP1, PARP2 | oncology | ovarian cancer | Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1, Fc1ccc(Cc2n[nH]c(=O)c3ccccc23)cc1C(=O)N1CCN(CC1)C(=O)C1CC1 | Launched | true | ACH-001239 |
BRD-K02130563-001-11-4 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.066322 | 0.490793 | 0.757596 | 0.543028 | 0.088365 | 0.118086 | panobinostat | HDAC inhibitor | HDAC1, HDAC2, HDAC3, HDAC4, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | multiple myeloma | Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1, Cc1[nH]c2ccccc2c1CCNCc1ccc(\C=C\C(=O)NO)cc1 | Launched | true | ACH-001239 |
BRD-K03390685-001-01-7 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.163408 | 0.677554 | 0.858342 | 0.545427 | 0.049603 | 0.088954 | cobimetinib | MEK inhibitor | null | oncology | melanoma | OC1(CN(C1)C(=O)c1ccc(F)c(F)c1Nc1ccc(I)cc1F)[C@@H]1CCCCN1 | Launched | true | ACH-001239 |
BRD-K03406345-001-21-1 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.364471 | -0.544177 | 0.086123 | 0.967272 | 0.000073 | null | azacitidine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL) | Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1, Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1 | Launched | true | ACH-001239 |
BRD-K03449891-001-08-6 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.238431 | 2.664766 | 0.354144 | 0.953392 | 6.019183 | 7.675947 | foretinib | VEGFR inhibitor | FLT1, FLT4, KDR, MET | null | null | COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1 | Phase 2 | true | ACH-001239 |
BRD-K03765900-001-01-9 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 2.733743 | 0.819207 | 0.22779 | 1 | 0.368397 | null | XL-647 | EGFR inhibitor, VEGFR inhibitor | EGFR, EPHB4, ERBB2, FLT4, KDR | null | null | COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1 | Phase 3 | true | ACH-001239 |
BRD-K05804044-001-18-5 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.32856 | 2.781672 | 0.754983 | 0.67541 | 0.091734 | 0.134786 | AZ-628 | RAF inhibitor | BRAF, RAF1 | null | null | Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1 | Preclinical | true | ACH-001239 |
BRD-K06814349-304-02-7 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.950571 | -2.291057 | -0.307613 | 0.975345 | 0.077197 | null | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-001239 |
BRD-K08109215-001-06-4 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 1.116854 | 0.023915 | -0.002992 | 1 | 177.503631 | null | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-001239 |
BRD-K08542803-001-02-3 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.111802 | 7.08641 | 0.705173 | 0.668238 | 0.266518 | 0.276213 | gambogic-acid | caspase activator | BCL2 | null | null | CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C | Phase 2 | true | ACH-001239 |
BRD-K08547377-001-04-4 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.438345 | 4.155211 | 0.343611 | 0.702329 | 0.05838 | 0.096612 | irinotecan | topoisomerase inhibitor | TOP1, TOP1MT | oncology | colorectal cancer | CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12 | Launched | true | ACH-001239 |
BRD-K08799216-001-05-3 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 1.698688 | 0.1411 | 0.031957 | 1 | 0.030606 | null | pelitinib | EGFR inhibitor | EGFR | null | null | CCOc1cc2ncc(C#N)c(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN(C)C | Phase 2 | true | ACH-001239 |
BRD-K09951645-001-11-8 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.397802 | 1.822453 | 0.854931 | 0.54568 | 0.006564 | 0.015687 | dabrafenib | RAF inhibitor | BRAF, LIMK1, NEK11, RAF1, SIK1 | oncology | melanoma | CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F | Launched | true | ACH-001239 |
BRD-K11630072-001-13-2 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.805206 | 0.107409 | -0.035979 | 0.870929 | 0.000127 | null | carmofur | thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O | Launched | true | ACH-001239 |
BRD-K12184916-001-19-6 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.566721 | 1.505824 | 0.363687 | 0.769171 | 0.055309 | null | NVP-BEZ235 | mTOR inhibitor, PI3K inhibitor | ATR, MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1 | Phase 2 | true | ACH-001239 |
BRD-K13049116-001-04-0 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.784243 | -1.437127 | 0.229999 | 0.871563 | 0.197361 | null | BMS-754807 | IGF-1 inhibitor | AKT1, IGF1R | null | null | C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1 | Phase 2 | true | ACH-001239 |
BRD-K13390322-001-06-3 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.989538 | -2.060367 | -0.107614 | 0.994763 | 0.078557 | null | AT-7519 | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK9 | null | null | Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1 | Phase 2 | true | ACH-001239 |
BRD-K13662825-001-07-5 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.176145 | 2.556125 | 0.817635 | 0.649569 | 0.040348 | 0.04782 | dinaciclib | CDK inhibitor | CDK1, CDK2, CDK5, CDK9 | null | null | CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO | Phase 3 | true | ACH-001239 |
BRD-K14109347-001-03-4 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 1.146347 | -0.098768 | -0.120637 | 1 | 314,979.783208 | null | LY2603618 | CHK inhibitor | CHEK1 | null | null | Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1 | Phase 2 | true | ACH-001239 |
BRD-K15600710-066-05-8 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.193777 | 1.822399 | 0.52966 | 0.87478 | 2.255397 | 2.951656 | obatoclax | BCL inhibitor | BCL2 | null | null | COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 | Phase 3 | true | ACH-001239 |
BRD-K17555800-003-02-3 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 1.2744 | 0.185987 | -0.099055 | 1 | 1.025577 | null | talmapimod | p38 MAPK inhibitor | MAPK11, MAPK14 | null | null | C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C | Phase 2 | true | ACH-001239 |
BRD-K17610631-001-03-3 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 2.169974 | 0.679273 | 0.556368 | 1 | 3.462812 | null | indisulam | CDK inhibitor | CA1, CA12, CA14, CA2, CA6, CA7, CA9 | null | null | NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12 | Phase 2 | true | ACH-001239 |
BRD-K17894950-001-14-3 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 1.337051 | 0.042288 | -0.043722 | 1 | 0.006289 | null | indirubin | CDK inhibitor, glycogen synthase kinase inhibitor | CDK1, CDK5, GSK3A | null | null | O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O | Phase 2/Phase 3 | true | ACH-001239 |
BRD-K18961567-001-01-1 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 1.566194 | 3.143047 | 0.295164 | 1 | 0.436507 | null | LY2801653 | MET inhibitor | MET | null | null | Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1 | Phase 2 | true | ACH-001239 |
BRD-K19540840-001-09-4 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 5.176213 | 0.623006 | 0.811713 | 1 | 6.148207 | null | saracatinib | src inhibitor | ABL1, LCK, SRC, YES1 | null | null | CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1 | Phase 2/Phase 3 | true | ACH-001239 |
BRD-K19687926-001-04-1 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 1.003984 | -0.380966 | -0.492022 | 1 | 0.296631 | null | lapatinib | EGFR inhibitor | EGFR, ERBB2 | oncology | breast cancer | CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1 | Launched | true | ACH-001239 |
BRD-K19796430-001-05-6 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 1.033992 | -0.263969 | -0.025475 | 1 | 0.857268 | null | sonidegib | smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1 | Launched | true | ACH-001239 |
BRD-K22064724-001-01-8 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.16935 | 5.232855 | 0.78628 | 0.727163 | 0.412706 | 0.446645 | napabucasin | STAT inhibitor | STAT3 | null | null | CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O | Phase 3 | true | ACH-001239 |
BRD-K22822991-001-02-3 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 1.145277 | 4.477093 | 0.118366 | 1 | 0.18271 | null | odanacatib | cathepsin inhibitor | CTSK | null | null | CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N | Phase 3 | true | ACH-001239 |
BRD-K23228615-001-02-8 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | -0.026189 | 1.712346 | 0.527875 | 0.918909 | 5.577138 | 5.413314 | GDC-0980 | mTOR inhibitor, PI3K inhibitor | FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK | null | null | C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1 | Phase 2 | true | ACH-001239 |
BRD-K23984367-001-07-5 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 1.235826 | 0.664326 | 0.078594 | 1 | 0.076762 | null | sorafenib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET | oncology | renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1 | Launched | true | ACH-001239 |
BRD-K26026438-001-01-0 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 2.349435 | 3.732713 | 0.470435 | 1 | 6.807771 | null | tucatinib | EGFR inhibitor | ERBB2 | null | null | Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 | Phase 2 | true | ACH-001239 |
BRD-K28822270-001-03-7 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.749383 | 0.024612 | -0.061452 | 0.881204 | 5.628462 | null | resminostat | HDAC inhibitor | HDAC1, HDAC3, HDAC6, HDAC8 | null | null | CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO | Phase 2 | true | ACH-001239 |
BRD-K29905972-001-06-3 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.767624 | 0.548297 | 0.148972 | 0.867514 | 0.03559 | null | axitinib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, FLT1, FLT4, KDR, PLK4 | oncology | renal cell carcinoma (RCC) | CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1 | Launched | true | ACH-001239 |
BRD-K30577245-001-05-0 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 1.948282 | 3.407966 | 0.601251 | 1 | 0.014286 | null | docetaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1 | oncology | breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C | Launched | true | ACH-001239 |
BRD-K31928526-001-02-1 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.723106 | -0.149857 | -0.160611 | 0.89474 | 0.002601 | null | barasertib | Aurora kinase inhibitor | AURKA, AURKB | null | null | CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O | Phase 2/Phase 3 | true | ACH-001239 |
BRD-K33379087-001-07-5 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 2.044805 | 1.549706 | 0.688637 | 1 | 2.855204 | null | tivantinib | tyrosine kinase inhibitor | MET | null | null | O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23 | Phase 3 | true | ACH-001239 |
BRD-K33610132-001-02-9 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 1.839824 | 2.812869 | 0.783105 | 1 | 0.645964 | null | rociletinib | EGFR inhibitor | EGFR | null | null | COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O | Phase 3 | true | ACH-001239 |
BRD-K35520305-001-16-9 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.749269 | -0.799003 | 0.089882 | 0.974212 | 0.000783 | null | dacarbazine | DNA alkylating agent | PGD, POLA2 | oncology, hematologic malignancy | melanoma, Hodgkin's lymphoma | CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O | Launched | true | ACH-001239 |
BRD-K36627727-001-05-4 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.755703 | 0.31225 | -0.029471 | 0.912381 | 0.700828 | null | tamibarotene | retinoid receptor agonist | RARA, RARB | hematologic malignancy | acute promyelocytic leukemia (APL) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12 | Launched | true | ACH-001239 |
BRD-K36788280-001-01-2 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.864584 | -0.110606 | -0.030972 | 0.915076 | 9.591482 | null | ribociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1 | Launched | true | ACH-001239 |
BRD-K37379014-001-02-0 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.870347 | -7.921351 | 0.18138 | 0.899037 | 0.018219 | null | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-001239 |
BRD-K38332599-001-01-3 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 44.27163 | 0.537238 | -0.020878 | 1 | 7,532,362,170.668449 | null | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-001239 |
BRD-K38527262-300-01-0 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.141561 | 10.70546 | 0.729033 | 0.822303 | 1.234878 | 1.273875 | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-001239 |
BRD-K38852836-001-02-1 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.115621 | 1.260488 | 0.724616 | 0.552326 | 0.018411 | 0.022682 | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-001239 |
BRD-K41859756-001-06-8 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.14432 | 4.848559 | 0.887425 | 0.522508 | 0.011139 | 0.011949 | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-001239 |
BRD-K42495768-001-01-7 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 1.08252 | 0.724947 | -0.017909 | 1 | 0.152147 | null | tasisulam | apoptosis stimulant | null | null | null | Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1 | Phase 3 | true | ACH-001239 |
BRD-K42898655-001-01-8 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.908841 | -0.698496 | -0.054865 | 0.936739 | 0.038348 | null | temsirolimus | mTOR inhibitor | MTOR | oncology | renal cell carcinoma (RCC) | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO | Launched | true | ACH-001239 |
BRD-K43389675-001-02-1 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.057062 | 1.138565 | 0.784555 | 0.756163 | 0.856191 | 0.952346 | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-001239 |
BRD-K44408410-001-17-6 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.862251 | -1.187446 | -0.000666 | 0.892716 | 1.251988 | null | 2-methoxyestradiol | hypoxia inducible factor inhibitor | COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB | null | null | COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O | Phase 2 | true | ACH-001239 |
BRD-K46386702-001-02-1 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.839946 | -4.670609 | -0.107384 | 0.919976 | 0.078087 | null | ARRY-334543 | EGFR inhibitor | ERBB2 | null | null | C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 | Phase 2 | true | ACH-001239 |
BRD-K49350383-001-14-5 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 1.399953 | 2.435696 | 0.479645 | 1 | 0.610541 | null | thioguanine | purine antagonist | IMPDH1, IMPDH2 | hematologic malignancy | acute myeloid leukemia (AML) | Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1 | Launched | true | ACH-001239 |
BRD-K50168500-001-07-9 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 2.245041 | 0.673652 | 0.577213 | 1 | 1.510002 | null | canertinib | EGFR inhibitor | AKT1, EGFR, ERBB2, ERBB4 | null | null | Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl | Phase 3 | true | ACH-001239 |
BRD-K51791723-003-01-7 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.240176 | 1.085928 | 0.632283 | 0.747624 | 0.409261 | 0.747824 | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-001239 |
BRD-K51967704-001-03-6 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.127139 | 6.451749 | 0.656291 | 0.743157 | 0.575198 | 0.601957 | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-001239 |
BRD-K52313696-001-12-3 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.489228 | 1.383311 | 0.239252 | 0.903792 | 1.706964 | null | tacedinaline | HDAC inhibitor | HDAC1 | null | null | CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N | Phase 3 | true | ACH-001239 |
BRD-K53414658-001-08-2 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.990405 | -0.220366 | -0.027074 | 0.993186 | 6.516519 | null | tivozanib | VEGFR inhibitor | FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB | null | null | COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC | Phase 3 | true | ACH-001239 |
BRD-K54256913-001-08-7 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 2.983118 | 1.383211 | 0.637468 | 1 | 1.332504 | null | MK-1775 | WEE1 kinase inhibitor | WEE1 | null | null | CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1 | Phase 2 | true | ACH-001239 |
BRD-K54955827-001-02-2 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.865252 | 0.002441 | -0.050865 | 0.937647 | 29,168,369,417,778,626,000,000,000 | null | niraparib | PARP inhibitor | PARP1 | oncology | primary peritoneal cancer (PPC) | NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1 | Launched | true | ACH-001239 |
BRD-K54997624-001-06-0 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 1.515185 | 1.509912 | 0.335562 | 1 | 0.171347 | null | alpelisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | null | null | Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F | Phase 3 | true | ACH-001239 |
BRD-K55187425-236-05-2 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 1.752206 | 2.735467 | 0.576734 | 1 | 0.20567 | null | rigosertib | cell cycle inhibitor, PLK inhibitor | PLK1 | null | null | COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1 | Phase 3 | true | ACH-001239 |
BRD-K56343971-001-14-8 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.453759 | 5.182673 | 0.599532 | 0.834814 | 0.531447 | 0.841316 | vemurafenib | RAF inhibitor | BRAF, RAF1 | oncology | melanoma | CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F | Launched | true | ACH-001239 |
BRD-K56981171-001-02-8 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.959208 | -0.93323 | -0.357999 | 0.976196 | 0.179156 | null | brigatinib | ALK tyrosine kinase receptor inhibitor, EGFR inhibitor | ALK, EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1 | Launched | true | ACH-001239 |
BRD-K57080016-001-15-9 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.459792 | 2.091259 | 0.828943 | 0.752177 | 0.116552 | 0.389013 | selumetinib | MEK inhibitor | MAP2K1 | null | null | Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO | Phase 3 | true | ACH-001239 |
BRD-K58435339-001-03-0 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.07738 | 0.706445 | 0.509123 | 0.541453 | 0.080562 | 0.102211 | AT13387 | HSP antagonist | HSP90AA1 | null | null | CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O | Phase 2 | true | ACH-001239 |
BRD-K58529924-001-01-5 | ACH-001239 | WM2664_SKIN | MTS010 | 1 | 0.627726 | 0.564376 | -0.005785 | 0.859773 | 0.328494 | null | ONC201 | AKT inhibitor, MAP kinase inhibitor | TNFSF10 | null | null | Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O | Phase 2 | true | ACH-001239 |
Subsets and Splits